Hypothesis

Chronic aging reduces hepatic and intestinal expression of the PXR co‑activator SRC‑1 (NCOA1), diminishing PXR transcriptional activity at barrier‑gene promoters despite adequate luminal IPA levels. This co‑activator deficit explains why IPA fails to preserve tight‑junction integrity in aged organisms, even though the ligand‑receptor interaction remains intact.

Mechanistic Basis

IPA activates PXR with a Kd of 8.7 µM, leading to recruitment of co‑activators such as SRC‑1 and MED1 to drive transcription of occludin, ZO‑1 and MUC2/4 2. In young mice, SRC‑1 is abundant, allowing robust barrier‑gene upregulation and NF‑κB suppression. Aging is linked to increased DNA methylation at the SRC‑1 promoter and elevated histone deacetylase activity, which attenuate SRC‑1 transcription 1. Consequently, PXR occupies response elements but cannot efficiently assemble the transcriptional complex, resulting in blunted barrier‑gene expression. The tissue‑selectivity of IPA‑PXR signaling (intestinal activation without hepatic CYP3A4 induction) may stem from differential SRC‑1 isoforms: intestinal epithelium expresses SRC‑1a, which retains responsiveness to IPA‑PXR, whereas hepatocytes predominantly express SRC‑1b, which is more susceptible to age‑related silencing 3.

Testable Predictions

1. Aged mice (≥20 months) will show unchanged colonic IPA concentrations but significantly reduced SRC‑1 mRNA and protein levels in intestinal epithelium compared with young controls.
2. Chromatin immunoprecipitation (ChIP) for PXR at the occludin and MUC2 promoters will reveal comparable receptor occupancy across ages, whereas ChIP for SRC‑1 will be markedly diminished in aged tissue.
3. Pharmacological or genetic restoration of SRC‑1 (e.g., AAV‑mediated SRC‑1a overexpression) in aged mice will rescue IPA‑induced barrier enhancement, normalizing transepithelial electrical resistance and reducing FITC‑dextran permeability.
4. In aged PXR‑knockout mice, SRC‑1 overexpression will not restore barrier function, confirming that SRC‑1 acts downstream of PXR.

Experimental Approach

• Cohorts: Young (3‑month) and aged (24‑month) C57BL/6J mice, both conventional and germ‑free, colonized with IPA‑producing Clostridium sporogenes or a non‑producing mutant.
• Measurements: LC‑MS quantification of luminal and serum IPA; qPCR and Western blot for SRC‑1 isoforms; ChIP‑seq for PXR and SRC‑1 at barrier‑gene loci; intestinal permeability assays (FITC‑dextran, Evans blue); histology for tight‑junction protein localization.
• Intervention: AAV8‑Src1a delivery via retrograde colonic infusion; control AAV8‑GFP.
• Readouts: Compare barrier outcomes between IPA‑treated and vehicle groups within each age and genotype.

Falsifiability

If aged mice exhibit normal SRC‑1 levels and PXR‑SRC‑1 co‑occupancy at barrier promoters yet still lack IPA‑mediated protection, the hypothesis is refuted. Conversely, demonstration that SRC‑1 loss correlates with barrier decline and that its rescue restores IPA efficacy would support the proposed mechanism.